Mr. Damien McCallion:

Our sole focus, and we have made movement with two of the laboratories on their turnaround times, is to address the third lab so that we can get the programme back to an even keel. That allows us to move on with HPV primary screening. We would love to see it go in this year but whether we can do that will be contingent on the tender process. That will be the critical path, to identify a partner to work with us to get this in place, in as short a time as possible and, to echo Dr. Doherty's point, in a structured sensible safe way. That is our objective.